Fibrostenosing Crohn’s Disease research hub

A Phase 2b, Randomized, Placebo-controlled, Double-blind, Dose-ranging Trial to Assess the Efficacy and Safety of Ontunisertib in Patients with Fibrostenosing Crohn’s Disease

This study tests a new medicine called ontunisertib for people with Crohn's disease who have narrowed sections in their bowel. Researchers want to find out if this daily capsule can reduce tough scar tissue, help widen the bowel, and improve symptoms compared to a dummy pill over one year.